Castleman’s disease- a diagnostic dilemma

Anupama Barua*, Kostas Vachlas, Richard Milton and James Andrew Charles Thorpe

Abstract

Castleman’s disease is a benign lymphoproliferative disease characterised by hyperplasia of lymphoid follicles. It can affect any lymph nodes in the body. Here we describe a caucasian patient who presented with six months history of shortness of breath with CT scan confirming an 8 cm segment of consolidated lung in left hilum. PET scan revealed a mass measuring 68x80x55 mm extending from the left hilum out into the left upper lobe containing area of calcification with SUV max 4.8. The differential diagnosis included atypical sequestration, hamartoma and primary lung malignancy. The patient underwent left video assisted enucleation of the lesion. The histology confirmed the diagnosis of Castleman’s disease.

Keywords: Benign lung lesion, Castleman’s disease and VATS

Background

Castleman’s disease is known as giant or angiofollicular lymph node hyperplasia, lymphoid hamartoma, or angiofollicular lymph node hyperplasia. It is named after Dr Benjamin Castleman who described this disease in 1954 from Massachusetts General Hospital [1]. The aetiology of the disease is unknown. It can develop in a single lymph node or series of lymph nodes. Castleman’s disease has been described as two clinical identities (i) unicentric/solitary/localised that involves single site for which removal of lymph node is curative and (ii) multicentric or systemic form of Castleman’s disease, which is associated with involvement of multiple lymph nodes and presents with systemic symptoms. Treatment of the systemic form involves corticosteroid; systemic chemotherapy or radiotherapy can be considered for disease control. This report presents a case of hyaline vascular variant of Castleman’s disease which was treated with left video assisted thoracoscopic surgery.

Case presentation

A 24 year old non-smoking caucasian lady presented with six months history of shortness of breath and productive cough, which did not improve with antibiotics. Clinical examination identified a bilateral significant wheeze. Routine haematological and biochemistry tests were normal. Her FEV₁ was 1.6 l (55% predicted) and FVC 3.04 l (92% predicted). CT revealed an 8 cm well demarcated segment of consolidated lung in the left hilum (Figure 1). On PET scan (Figure 2) it was hypermetabolic returning an SUV max 4.8. The radiological appearance was suggestive of sequestration or hamartoma. A CT-guided biopsy was indeterminate and she was therefore referred for surgery. During VATS, the lesion was identified in the left hilum in a haemorrhagic capsule.

The lesion was partially enucleated; a feeding bronchus, artery and vein were ligated. The histology from the left upper lobe mass revealed hyaline vascular variant of Castleman’s disease. Postoperative recovery was uneventful.

Discussion

In this case, Castleman’s disease presented as a mass located in the left lung near to the hilum. Attempts at a preoperative diagnosis were unhelpful. CT guided biopsy was inconclusive. She was therefore referred for surgery for diagnostic and therapeutic reasons.

Castleman’s disease may affect anyone from adolescent to seventh decade with equal sex distribution. It is reported to involve any lymph nodes in the body such as cervical (42%), mediastinal (31%), intraabdominal (18%), and retroperitoneal (5%). Only 5% can involve extranodal lymph node [2]. Unicentric Castleman’s disease presents with a slow growing mass, while multicentric variant manifests as fever, malaise, weight loss and generalised lymphadenopathy.

Histologically three types are identified - hyaline vascular variety (90%) and plasma cells type (8-9%) and
mediastinal or hilar mass with a differential diagnosis that includes thymoma, lymphoma, neurogenic tumor or bronchial adenoma. In contrast, multicentric Castleman's disease may appear as bilateral hilar and mediastinal enlargement or diffuse reticulonodular pulmonary infiltrations [6].

CT scanning reveals three morphologic patterns of unicentric thoracic Castleman's disease: a solitary, noninvasive mass (50% of cases); a dominant mass with involvement of contiguous structures (40% of cases); or a matted lymphadenopathy confined to a single mediastinal compartment (10% of cases) [6]. Hypervascularity of the lesion may reveal homogeneously intense contrast enhancement in CT. 5–10% of Castleman's disease demonstrated intraliesional calcifications, typically being discrete, coarse, or distinctive with an "arborizing" pattern in enhanced CT [6]. For thoracic Castleman's disease MRI can be used as it demonstrates the extent of the tumour, clarifies its relationship to the bronchovascular structures and shows the feeding vessels. Similar to other inflammatory disease, Castleman's disease shows mild to moderate FDG uptake in PET scan. Histological diagnosis before surgical removal can be done by CT guided biopsy, EUS and EBUS if the anatomical position permits.

Surgical resection is diagnostic and curative for unicentric Castleman's disease. As described before, corticosteroid therapy, chemotherapy and monoclonal antibody treatment are suitable for multicentric Castleman's disease. Surgical excision may not be easy in unicentric hyaline vascular type due to high vascularity. It may be associated with massive haemorrhage at excision and pneumonectomy has been reported for massive bleeding [7]. Embolization of the feeding artery before surgery can be considered to prevent intraoperative bleeding. Complete surgical resection is the gold standard treatment in unicentric Castleman's disease and is also required for complete recovery in the majority of cases. The prognosis is good after surgical excision in unicentric Castleman's disease, and 5-year survival is 100% [8]. On the contrary, multicentric Castleman's disease has a poor prognosis with a median survival of thirty months. Nevertheless, splenectomy with systemic chemotherapy and steroids can improve the prognosis in multicentric Castleman's disease [9]. Although Castleman's disease is classed as a benign disease, long term follow up is required as recurrence can happen as late as eight years after the diagnosis of the disease [8].

**Conclusion**

This is a rare case report of Castleman's disease. It is important to remember Castleman's disease as a differential diagnosis in benign lung parenchymal lesion. In this case the patient was treated by VATS enucleation of the lesion avoiding unnecessary lung resection. To our knowledge, this is the first lesion which was removed by keyhole surgery.
Consent
Written informed consent was obtained from the patient for publication. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Abbreviation
VATS: Video assisted thoracoscopic surgery.

Competing interests
The authors declare that they have no competing interests.

Authors’ contribution
AB involved in study design and drafted the manuscript, VH helped to draft the manuscript, RM & JACT revised the manuscript. All authors read and approved the final manuscript.

Received: 22 May 2014 Accepted: 2 October 2014
Published online: 28 November 2014

References
1. Castleman B, McNeely BU, +MACNEELY BU: Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 22–1971. N Engl J Med 1971, 284(22):1260–1266.
2. Danon AD, Krishnan J, Frizzera G: Morpho-immunophenotypic diversity of Castleman’s disease, hyaline-vascular type: with emphasis on a stromarich variant and a new pathogenetic hypothesis. Virchows Arch A Pathol Anat Histopathol 1993, 423(5):369–382.
3. Keller AR, Hochholzer L, Castleman B: Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 1972, 29(3):670–683.
4. Peterson BA, Frizzera G: Multicentric Castleman’s disease. Semin Oncol 1993, 20(6):636–647.
5. Khan J, von Sinner W, Akhtar M, Bazbarahi M: Castleman’s disease of the chest. Magnetic resonance imaging features. Chest 1994, 105(5):1608–1610.
6. McAdams HP, Rosado-de-Christenson M, Fishback NF, Templeton PA: Castleman disease of the thorax: radiologic features with clinical and histopathologic correlation. Radiology 1998, 209:221–228.
7. Racil H, CheikhRouhou S, Ismail O, Hantous-Zannad S, Chaouch N, Zarrouk M, Smati B, Mezni F, Chabbou A: Castleman’s disease: an intrapulmonary form with intrafissural development. Scientific World Journal 2009, 9:940–945.
8. Shahidi H, Myers JL, Kvale PA: Castleman’s Disease. Mayo Clin Proc 1995, 70(10):969–977.
9. Lerza R, Castello G, Truiui M, Ballarino P, Tredici S, Cavallini D, Pannaccili I: Splenectomy induced complete remission in a patient with multicentric Castleman’s disease and autoimmune hemolytic anemia. Ann Hematol 1999, 78(4):193–196.

doi:10.1186/s13019-014-0170-0
Cite this article as: Barua et al.: Castleman’s disease- a diagnostic dilemma. Journal of Cardiothoracic Surgery 2014 19:170.